Skip to content

effect of propolis in COVID-19

The effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200326046868N1
Enrollment
88
Registered
2020-05-09
Start date
2020-05-21
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Other coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: The propolis supplement is taken as a 500 mg capsule twice a day for 1 month. Intervention 2: Control group: The placebo is taken as a capsule twice a day for 1 mon

Sponsors

Abadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 years Laboratory confirmation of Covid-19 (2019-nCoV Real-Time RT-PCR)

Exclusion criteria

Exclusion criteria: Pregnancy and lactation, a history of allergies to honey and bee products, uncontrolled underlying disease including neuropsychiatric problems, diabetes, thyroid disorders, heart disease, chronic liver or kidney failure, and autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
Cough. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Oxygen saturation. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Respiratory rate. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;Body temperature. Timepoint: First and 30 days after the intervention. Method of measurement: Clinical examination.;LI-6. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;TNF alpha. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;Crp-hs. Timepoint: First and 30 days after the intervention. Method of measurement: ELISA.;CBC. Timepoint: First and 30 days after the intervention. Method of measurement: Cell counter.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Malihi

Abadan University of Medical Sciences

r.malihi@abadanums.ac.ir+98 61 3555 0592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026